Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase 2 neoadjuvant gemcitabine + cisplatin with or without durvalumab followed by adjuvant durvalumab in localized biliary tract cancer
KCT0004415Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- May 2020
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of durvalumab in biliary cancer and gallbladder cancer (2 arms), sponsored by AstraZeneca. Started May 2020; status: active, not recruiting.
02
Drugs
durvalumab
03
Conditions
biliary cancergallbladder cancer
Beyond the preview
Go deeper on KCT0004415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004415.